Memory Protection in the Digital Health Era: A New Direction for Alzheimer's Disease Prevention in Nigeria
DOI:
https://doi.org/10.64229/1ts56h34Keywords:
Alzheimer's Disease, Digital Therapeutics, Nigeria, Cognitive Impairment, Neurodegenerative Diseases, Digital Health, Cognitive Assessment, Low- And Middle-Income CountriesAbstract
Alzheimer's disease (AD) and other neurodegenerative conditions present significant public health challenges in Nigeria, with rising prevalence due to demographic aging and limited healthcare infrastructure. Digital therapeutics (DTx) offer promising approaches to address these challenges through evidence-based software interventions for prevention, management, and treatment of cognitive disorders. This perspective examines the current landscape of AD in Nigeria and explores the potential applications of digital therapeutics within this context. We analyze the unique challenges and opportunities for implementing DTx in Nigeria's healthcare system, considering cultural, infrastructural, and policy factors. We also propose a framework for future research directions integrating digital cognitive assessments, interventions, and monitoring systems tailored to the Nigerian population. By addressing the specific needs and constraints of the Nigerian healthcare environment while leveraging global advancements in digital health, researchers can develop effective, scalable solutions to mitigate the growing burden of Alzheimer's disease in Nigeria and similar low- and middle-income countries.
References
[1]Jing Huang, Nancy A Perrin, Adam P Spira, Sarah L Szanton, George W Rebok, Chakra Budhathoki, Nalaka S Gooneratne, Junxin Li, Sleep disturbance and cognitive trajectories among older adults with subjective cognitive decline: the roles of age and sleep treatment, Sleep, 2025;, zsaf234, https://doi.org/10.1093/sleep/zsaf234
[2]Guo, HH., Liang, DX., Zhang, Q. et al. Associations between sleep quality, plasma neurofilament light, and cognition in older adults without dementia. Transl Psychiatry 15, 169 (2025). https://doi.org/10.1038/s41398-025-03389-1
[3]Cummings J, Lee G, Zhong K, et al. Alzheimer's disease drug development pipeline: 2021. Alzheimer's Dement. 2021; 7:e12179. https://doi.org/10.1002/trc2.12179
[4]O’Neill, A., Edvardsson, K. & Hooker, L. (2022). Clinical supervision practice by community-based child and family health nurses: A mixed-method systematic review. Journal of Advanced Nursing, 78, 1588–1600. https://doi.org/10.1111/jan.15191
[5]Exalto LG, Hendriksen HMA, Barkhof F, et al. Subjective cognitive decline and self-reported sleep problems: The SCIENCe project. Alzheimer's Dement. 2022; 14:e12287. https://doi.org/10.1002/dad2.12287
[6]Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's Dement. 2020; 16: 1078–1094. https://doi.org/10.1002/alz.12123
[7]van der Linde, R.M., Stephan, B.C., Dening, T. and Brayne, C. (2013), Instruments to measure behavioural and psychological symptoms of dementia: changing use over time. Int J Geriatr Psychiatry, 28: 433-435. https://doi.org/10.1002/gps.3856
[8]Goksel Guven, Matthias P. Hilty, Can Ince; Microcirculation: Physiology, Pathophysiology, and Clinical Application. Blood Purif 28 February 2020; 49 (1-2): 143–150. https://doi.org/10.1159/000503775
[9]Jack, C.R., Jr., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtzman, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T., Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sperling, R., Contributors, Elliott, C., Masliah, E., Ryan, L. and Silverberg, N. (2018), NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14: 535-562. https://doi.org/10.1016/j.jalz.2018.02.018
[10]Jongsiriyanyong S, Limpawattana P. Mild Cognitive Impairment in Clinical Practice: A Review Article. American Journal of Alzheimer’s Disease & Other Dementias®. 2018;33(8):500-507. doi:10.1177/1533317518791401
[11]Livingston, G., et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, 396(10248), 413–446. https://doi.org/10.1016/S0140-6736(20)30367-6
[12]Mukaetova-Ladinska, Elizabeta B.a,b; Kronenberg, Goloc,d; Raha-Chowdhury, Rumae. COVID-19 and neurocognitive disorders. Current Opinion in Psychiatry 34(2):p 149-156, March 2021. | https://doi.org/10.1097/YCO.0000000000000687
[13]Hayes, S.C. (2019), Acceptance and commitment therapy: towards a unified model of behavior change. World Psychiatry, 18: 226-227. https://doi.org/10.1002/wps.20626
[14]Ngandu, T., et al. (2015). A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring: The FINGER trial. Lancet, 385(9984), 2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
[15]Olayinka, Olaniyi O., Mbuyi, Nadine N., Epidemiology of Dementia among the Elderly in Sub-Saharan Africa, International Journal of Alzheimer’s Disease, 2014, 195750, 15 pages, 2014. https://doi.org/10.1155/2014/195750
[16]Weintraub S, Karpouzian-Rogers T, Peipert JD, et al. ARMADA: Assessing reliable measurement in Alzheimer’s disease and cognitive aging project methods. Alzheimer's Dement. 2022; 18: 1449–1460. https://doi.org/10.1002/alz.12497
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Singhma Soyouzee (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
